Research Article
A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer
| | AEs | 2-weekly group (N = 9) | 3-weekly group (N = 15) | | Grade I/II, n (%) | Grade III, n (%) | All grade I/II, n (%) |
| | Hematological AEs | | Anemia | 8 (88.89) | — | 13 (86.67) | | Lymphopenia | 6 (66.67) | — | 5 (33.33) | | Thrombocytopenia | 2 (22.22) | — | 2 (13.33) | | Neutropenia | 3 (33.33) | 2 (22.22) | — |
| | Nonhematological AEs | | Nausea | 1 (11.11) | — | 4 (26.67) | | Vomiting | 1 (11.11) | — | 6 (40) | | Weakness | 3 (33.33) | — | 9 (60) | | Hyperglycemia | 1 (11.11) | — | — | | Anorexia | — | — | 1 (6.67) | | Diarrhea | — | 2 (22.22) | 4 (26.67) | | Alteration in LFT | — | | 1 (6.67) | | Mouth ulcer | 1 (11.11) | — | — | | Constipation | 2 (22.22) | — | 6 (40) |
|
|
AE = adverse event, LFT = liver function test, NDLS = nanosomal docetaxel lipid suspension.
|
